Saw Palmetto
Serenoa repens
Popular prostate herb that rigorous trials found no better than placebo.
Mixed evidence
⚡Performance
Evidence tier
Mixed
Research weight
Citations
13 verified / 13
Classification
Performance
❝
What the evidence says. Conflicting results across studies; benefit uncertain.
What is Saw Palmetto?
Saw Palmetto (Serenoa repens) is a performance supplement used for marketed to ease lower urinary tract symptoms (luts) of benign prostatic hyperplasia (bph), such as weak stream, frequency, and nighttime urination — but the best evidence shows little to no benefit over placebo.. NutriDex grades the human evidence as Mixed. Saw palmetto (Serenoa repens) is an extract of the dwarf palm berry widely sold for benign prostatic hyperplasia and lower urinary tract symptoms, and more recently for hair loss. Although early, mostly small and lower-quality trials reported symptom improvement, larger and more rigorous studies did not confirm a benefit. The NIH-funded CAMUS randomized trial found that even at up to triple the standard dose (960 mg/day), saw palmetto was no better than placebo for urinary symptoms. The 2024 updated Cochrane review of 27 trials (4,656 men) concluded with high-certainty evidence that it produces little to no difference in urologic symptoms or quality of life. The evidence is best characterized as mixed: a positive early literature offset by robust modern trials showing no meaningful effect. Its main redeeming feature is a strong safety record, with adverse events comparable to placebo.
Purported Benefits
✓Marketed to ease lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH), such as weak stream, frequency, and nighttime urination — but the best evidence shows little to no benefit over placebo.
✓Early small/lower-quality trials suggested symptom relief; these positive signals did not hold up in larger, well-blinded, placebo-controlled studies.
✓Sometimes used for male-pattern hair loss based on weak 5-alpha-reductase inhibition; human evidence here is preliminary and far weaker than for finasteride/dutasteride.
✓A consistent finding across trials is that it is well tolerated, with a side-effect profile similar to placebo — so its main 'benefit' is safety, not efficacy.
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Lower urinary tract symptoms of BPH2024 Cochrane (27 RCTs, high certainty) and NIH CAMUS/STEP trials show little to no benefit over placebo, even at triple dose. | Strong | — no effect · negligible | 5 |
| Quality of life in BPHCochrane: QoL difference MD -0.20, clinically meaningless. | Strong | — no effect · negligible | 2 |
| Male-pattern hair lossOne small 90-day RCT (n=60) showed terminal hair gains; far weaker than finasteride/dutasteride. | Preliminary | ↑ benefit · small | 1 |
| Safety / tolerabilityConsistently well tolerated; adverse events similar to placebo (RR 1.01) over up to 72 weeks. | Strong | ↑ benefit | 2 |
Dosing & Compounds
Typical Dose
320 mg/day of a lipophilic berry extract standardized to 85-95% fatty acids and sterols, taken as 320 mg once daily or 160 mg twice daily (the dose used in most trials; higher doses up to 960 mg/day showed no added benefit).
Active Compounds
Safety & Cautions
Generally well tolerated; in trials adverse events (mild GI upset, headache, occasional decreased libido) occur at rates similar to placebo, with no signal of organ toxicity even at 960 mg/day. Because it has mild antiplatelet/anticoagulant potential, use cautiously with warfarin, clopidogrel, aspirin, or other blood thinners and stop 1-2 weeks before surgery; rare reports of bleeding and of liver or pancreas injury exist. It may have weak hormonal (anti-androgen/5-alpha-reductase) activity, so it can theoretically lower serum DHT and is contraindicated in pregnancy and breastfeeding and should be avoided by women who are or may become pregnant. It can modestly affect PSA interpretation in some contexts, so men should tell their clinician they take it before prostate cancer screening. Saw palmetto does not shrink the prostate or treat the underlying disease, so it should not replace evaluation of urinary symptoms or proven therapies (alpha-blockers, 5-alpha-reductase inhibitors); men with new, severe, or worsening LUTS, blood in the urine, or retention need medical assessment rather than self-treatment. Educational only — always check with your doctor or pharmacist before combining Saw Palmetto with any medicine.
Saw Palmetto drug interactions
Known or theoretical interactions between Saw Palmetto and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Saw Palmetto with any medicine.
Monitor
Finasteride / hormonal agents
May affect androgen pathways like finasteride and slightly raise bleeding risk; can confound PSA tests.
Possible weak 5-alpha-reductase inhibition plus mild antiplatelet activity. NCCIH — Saw Palmetto
Key Studies ★ 13 studies
Systematic review / meta-analysis
4,656 men (27 RCTs)
✓ PubMed
This 2024 updated Cochrane review found high-certainty evidence that Serenoa repens results in little to no difference in urologic symptoms (IPSS mean difference -0.90 points) or quality of life versus placebo in men with BPH-related LUTS.
Cochrane review
Franco 2023 (Cochrane)
✓ PubMed
In 27 RCTs (n=4,656), Serenoa repens produced little to no difference in urologic symptoms at 3-6 months (IPSS mean difference -0.90, 95% CI -1.74 to -0.07; high certainty).
Cochrane review
Franco 2023 (Cochrane, PMC full text)
✓ Full text
Updated Cochrane review found saw palmetto gives little to no quality-of-life benefit (MD -0.20, 95% CI -0.40 to 0.00) and no difference in adverse events vs placebo (RR 1.01, 95% CI 0.77-1.31).
Systematic review
Cochrane synopsis (AAFP)
✓ Full text
AAFP clinician synopsis of the 2023 Cochrane review states saw palmetto, alone or combined with other phytotherapeutics, does not improve urologic symptoms or quality of life at short- or long-term follow-up.
Meta-analysis
Trivisonno / Investig Clin Urol SR-MA (2021)
✓ PubMed
Independent GRADE systematic review and meta-analysis of 27 RCTs (4853 participants). Serenoa repens alone results in little to no difference in urinary symptom score, quality of life, and adverse events at short- and long-term follow-up; combination phytotherapy effects very uncertain.
Meta-analysis
Russo / Eur Urol Focus Network MA (2020)
✓ PubMed
Network meta-analysis of 22 RCTs (8564 patients) comparing hexanic/non-hexanic Serenoa repens, placebo and alpha-blockers. Saw palmetto showed no clinically meaningful improvement in IPSS or peak flow; SUCRA ranks (HESr 36.7%, nHESr 47.3%) trailed alpha-blockers (terazosin 99.6%), with benefit over placebo minimal.
Systematic review / meta-analysis
5,666 men (30 RCTs)
✓ Full text
The 2012 Cochrane review concluded that saw palmetto, alone or combined with other phytotherapeutic agents, did not improve urinary symptoms, peak urine flow, or prostate size compared with placebo.
Government agency evidence summary
Evidence review
✓ Source
NCCIH's provider summary states that high-quality research does not support a benefit of saw palmetto for BPH symptoms, while noting it is generally well tolerated.
Agency / regulator
NCCIH
✓ Source
NCCIH concludes saw palmetto is probably not helpful for BPH symptoms but is well tolerated, with mild infrequent adverse effects and no apparent effect on PSA levels.
Large randomized controlled trial
369 men
✓ PubMed
In this NIH-funded double-blind RCT (CAMUS, JAMA), escalating doses of saw palmetto up to 960 mg/day for 72 weeks did not reduce lower urinary tract symptoms more than placebo (change favored placebo by ~0.8 AUASI points).
RCT safety analysis
357 men
✓ PubMed
This safety analysis of the CAMUS trial found saw palmetto at doses up to 960 mg/day produced no evidence of toxicity, with adverse-event rates similar to placebo over 72 weeks.
RCT
SEREVELLE hair RCT (90-day)
✓ Full text
Randomized, double-blind, placebo-controlled trial (n=60) of a 160 mg saw palmetto fatty-acid extract found greater terminal hair count gains vs placebo at day 90 (anterior +11.3 hairs, p<0.001) with no adverse events.
RCT
Bent / STEP Trial, NEJM (2006)
✓ PubMed
Landmark NIH double-blind RCT, 225 men, saw palmetto 160 mg twice daily vs placebo for 1 year. No significant difference in AUASI (mean difference 0.04 point, 95% CI -0.93 to 1.01), maximal urinary flow, prostate size, residual volume, quality of life, or PSA; side effects similar.